Medication info

Dongkwang Dapagliflozin 5 mg (Dapagliflozin Monohydrate Mix)

Prescription medicationTabletOralExpired
Ingredient · strength
Dapagliflozin Anhydrous Lactose Mixture›7.635mg / 1 tablet
Manufacturer / importer
Dongkwang Pharmaceutical Co., Ltd.
Appearance
Yellow, bi-convex, round, film-coated tablets
Packaging
28 tablets/box [(7 tablets/PTP x 4)]
Approval status
Expired

MFDS item code 202005368 · Approved 2020.07.23

This product's status changed to Expired on 2025.07.23. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults · Children
Adult dose
Type 2 diabetes mellitus Monotherapy and add-on combination therapy The recommended dose of this medicine is 10mg once daily for monotherapy and add-on combination therapy with other glucose-lowering agents, such as insulin. When this medicine is used in combination with insulin or insulin secretagogues such as sulfonylureas, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. Initial combination therapy For patients with no prior experience of diabetes medication, when administered in combination with metformin, the recommended initial dose of this medicine is 5mg once daily or 10mg once daily. Special populations Renal impairment - eGFR less than 45 mL/min/1.73m2: Use of this medicine is not recommended for the purpose of improving glycemic control. - Patients on dialysis: Do not administer this medicine. Hepatic impairment No dose adjustment is required for patients with mild or moderate hepatic impairment. For patients with severe hepatic impairment, 5 mg is recommended as the starting dose. If well tolerated, this dose may be increased to 10mg. Elderly patients (≥ 65 years) Dose adjustment based on age is not recommended. Method of administration This medicine may be taken orally once daily at any time of the day, with or without food. The tablet should be swallowed whole.
Child dose
The efficacy and safety of dapagliflozin in children under 18 years of age have not been established. No relevant data are available.

Ingredients

Manufacturer
Dongkwang Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Difficulty in blood glucose control in patients with type 2 diabetes
View approved original text

This medication is an adjunct to diet and exercise to improve blood glucose control in patients with type 2 diabetes. It is initially administered alone but may be combined with other diabetes medications when adequate blood glucose control cannot be achieved with monotherapy alone. For example, it can be used in combination with medications like metformin, sulfonylureas, insulin, and sitagliptin. This combination therapy helps improve blood glucose control, enhancing the patient's health. It is used appropriately according to the individual treatment situation to assist in managing blood glucose levels in type 2 diabetes. In other words, this drug improves blood glucose control in patients with type 2 diabetes.

How to take

Adult dose

Type 2 diabetes mellitus Monotherapy and add-on combination therapy The recommended dose of this medicine is 10mg once daily for monotherapy and add-on combination therapy with other glucose-lowering agents, such as insulin. When this medicine is used in combination with insulin or insulin secretagogues such as sulfonylureas, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. Initial combination therapy For patients with no prior experience of diabetes medication, when administered in combination with metformin, the recommended initial dose of this medicine is 5mg once daily or 10mg once daily. Special populations Renal impairment - eGFR less than 45 mL/min/1.73m2: Use of this medicine is not recommended for the purpose of improving glycemic control. - Patients on dialysis: Do not administer this medicine. Hepatic impairment No dose adjustment is required for patients with mild or moderate hepatic impairment. For patients with severe hepatic impairment, 5 mg is recommended as the starting dose. If well tolerated, this dose may be increased to 10mg. Elderly patients (≥ 65 years) Dose adjustment based on age is not recommended. Method of administration This medicine may be taken orally once daily at any time of the day, with or without food. The tablet should be swallowed whole.

Child dose

The efficacy and safety of dapagliflozin in children under 18 years of age have not been established. No relevant data are available.

Precautions

This medication should not be used in certain patients. For instance, individuals who are allergic to the main ingredient or excipients of this drug, patients with type 1 diabetes, those with diabetic ketoacidosis, and individuals with lactose intolerance or certain genetic issues should not take this medication. Additionally, patients undergoing dialysis should not use this drug. Patients with fluid depletion or impaired kidney function should exercise caution when using this drug. This medication can cause blood pressure drops or changes in kidney function; therefore, it is essential to closely monitor fluid status and kidney function before and after administration. Particularly, elderly patients or those taking diuretics require more careful observation. This medication contains yellow dye, so patients allergic to or experiencing hypersensitivity to this component should also be cautious. The most common side effect that may occur during the use of this drug is genital infections. Other reported side effects include urinary tract infections, hypoglycemia, fluid volume reduction, diabetic ketoacidosis, and kidney function abnormalities. If side effects are suspected, immediate consultation with medical personnel is necessary. Serious side effects could include the rare occurrence of severe infections such as gangrene of the perineum (Fournier's gangrene), so if pain, swelling, or redness occurs in the genital or perineal areas, prompt medical attention should be sought. Pregnant or nursing women are advised not to use this medication, and if pregnancy is confirmed, the medication should be discontinued immediately. When used in combination with insulin or sulfonylureas, this drug can increase the risk of hypoglycemia, so in such cases, dosage adjustments of insulin or the respective medication may be necessary. Furthermore, this drug may have weight-reducing effects; thus, careful monitoring of weight changes is advised. There is no specific antidote in case of overdose, so appropriate treatment should be administered based on symptoms. Finally, routine checks on blood glucose levels should be performed while taking this medication, and caution regarding hypoglycemia symptoms should be maintained when driving or operating machinery. This medication should be taken strictly according to a physician's prescription and guidance, and any abnormal symptoms should be promptly discussed with a specialist.

Side effects

Vulvovaginitis, balanitis and related genital infections, urinary tract infections, fungal infections, perineal necrosis, hypoglycemia, decreased fluid volume, thirst, diabetic ketoacidosis, dizziness, constipation, dry mouth, low back pain, pain during urination, polyuria, nocturia, interstitial nephritis, vulvar itching, genital itching, elevated hematocrit, decreased creatinine clearance during initial treatment, dyslipidemia, elevated blood creatinine during initial treatment, elevated blood urea, weight loss, acute pyelonephritis, rash, angioedema, uroseptic shock, acute kidney injury, renal dysfunction, asthenia, pain, keratitis, chronic obstructive pulmonary disease, hemoptysis, cerebral hemorrhage, peripheral arterial occlusion, angina, myocardial infarction, bile duct stones, cholangitis, alcoholic liver cirrhosis, depression, suicide attempt, gastric adenocarcinoma, anaphylactic reaction, sensory disturbance, cerebral infarction, nerve compression, urinary tract infection, sinusitis, diverticulitis, pelvic inflammatory disease, pneumonia, pulmonary tuberculosis, herpes simplex, edema, fever, foreign body sensation, facial swelling, facial pain, warmth, influenza-like symptoms, chest pain, fatigue, vaginal discharge, menstrual irregularities, itching, hives, cold sweat, arthralgia, musculoskeletal pain, limb pain, muscle weakness, myalgia, osteoarthritis, ligament sprain, diabetic retinopathy, cough, shortness of breath, orthostatic hypotension, palpitations, insomnia, fatty liver, gallbladder polyp, tinnitus

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. Additionally, it is best to store the medication at a cool room temperature, specifically between 1 and 30 degrees Celsius. Avoid placing it in excessively hot or cold environments.

Appearance and packaging

Appearance

Yellow, bi-convex, round, film-coated tablets

Package unit

28 tablets/box [(7 tablets/PTP x 4)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.